Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $49.128 million which beat the analyst consensus estimate of $48.861 million by 0.55 percent. This is a 21.36 percent decrease over sales of $62.472 million the same period last year.